The historical rank and industry rank for Conduit Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:
CDT's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.87 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Competitive Comparison of Conduit Pharmaceuticals's 5-Year Yield-on-Cost %
For the Biotechnology subindustry, Conduit Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Conduit Pharmaceuticals's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Conduit Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Conduit Pharmaceuticals's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Conduit Pharmaceuticals 5-Year Yield-on-Cost % Related Terms
Thank you for viewing the detailed overview of Conduit Pharmaceuticals's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.
Conduit Pharmaceuticals (Conduit Pharmaceuticals) Business Description
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CDT has been successfully added to your